STOCK TITAN

Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will report financial results for the year ended December 31, 2023, and recent corporate updates on February 28, 2024. The live conference call and webcast will be held at 8:00 a.m. ET (9:00 p.m. HKT) on the same day. Listeners can access the webcast through the company's website and must register in advance. Dial-in details will be provided upon registration. A replay will be available on the website after the call.
Positive
  • None.
Negative
  • None.

- Company to Host Conference Call and Webcast on February 28, 2024, at 8:00 a.m. ET (9:00 p.m. HKT)

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the year ended December 31, 2023 and recent corporate updates, after the closing of the U.S. equity markets on Tuesday, February 27, 2024. The Company will host a live conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET (9:00 p.m. HKT).

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BIa1fd72e50c9e4117b696c49bdfa9f83b

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company's website.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:



Investor Relations:

Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:

Shaun Maccoun / Xiaoyu Chen

+1 (415) 317-7255 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Source: Zai Lab Limited

FAQ

When will Zai Lab Limited report financial results for the year ended December 31, 2023?

Zai Lab Limited will report financial results on February 28, 2024.

What is the ticker symbol for Zai Lab Limited?

The ticker symbol for Zai Lab Limited is ZLAB on NASDAQ and 9688 on HKEX.

How can listeners access the live webcast of the conference call?

Listeners can access the live webcast by visiting the Company's website at http://ir.zailaboratory.com and registering in advance.

Will a replay of the conference call be available?

Yes, a replay will be available shortly after the call and can be accessed by visiting the Company's website.

Zai Lab Limited American Depositary Shares

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Stock Data

1.61B
887.81M
1.83%
44.84%
3.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SHANGHAI

About ZLAB

zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve